This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD). Click on the activities below to explore valuable insights and clinical decision-making around:
- Therapy selection based on patient characteristics and disease progression
- Individualized dosing strategies and treatment intervals
- Monitoring response and adjusting therapy to reduce treatment burden
